瑞舒伐他汀联合常规治疗急性脑梗死疗效及对患者血清VS-2、sICAM-1和MMp2水平影响

Efficacy of Rosuvastatin Combined with Conventional Treatment in the Patients with Acute Cerebral Infarction and Influence on Serum Levels of VS-2,sICAM-1 and MMp2

目的:观察瑞舒伐他汀联合常规治疗急性脑梗死(ACI)的疗效及对患者血清血管抑制因子(VS-2)、可溶性细胞黏附因子-1(s ICAM-1)和基质金属蛋白酶2(MMp2)水平的影响。方法:ACI住院患者136例随机分为对照组和观察组各68例。对照组患者予常规治疗,观察组在对照组基础上加用瑞舒伐他汀片,两组疗程均为15 d。评价两组患者疗效与药品不良反应发生率,比较两组患者治疗前后血清VS-2、s ICAM-1、MMp2水平变化。结果:观察组有效率为92.65%,明显高于对照组的77.94%(P<0.05)。两组轻型、中型和重型患者治疗后VS-2、s ICAM-1和MMp2均较前明显降低(P<0.05),且观察组各型患者血清VS-2、s ICAM-1和MMp2水平明显低于对照组相同亚组(P<0.05);两组不同梗死灶亚组治疗后血清VS-2、s ICAM-1和MMp2均较治疗前明显降低(P<0.05),且观察组不同梗死灶亚组的各项指标水平明显低于对照组相同亚组(P<0.05)。两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:瑞舒伐他汀治疗ACI效果较好,可降低患者血清VS-2、s ICAM-1和MMp2水平,值得临床推广使用。

Objective： To observe the efficacy of rosuvastatin combined with the conventional treatment in the patients with acute cerebral infarction （ACI） and the influence on the serum levels of MMp2, vasostatin-2 and sICAM-1. Methods： Totally 136 patients with ACI were randomly divided into the routine treatment group and the rosuvastatin group with 68 ones in each. The patients in the routine treatment group were treated with the conventional treatment, and those in the rosuvastatin group were treated with rosuvastatin additionally. The treatment course was 15 days. The efficacy, adverse drug reactions and the changes of MMp2, vasostatin-2 and sI- CAM-1 in the two groups were compared. Results： The effective rate was 92.65% in rosuvastatin group and that was 77.94% in the routine treatment group, and the difference was statist!cally significant （P 〈 0.05）. After the treatment, the levels of MMp2, vasosta- tin-2 and sICAM-1 for the mild, medium and severe types in the two groups were significantly decreased when compared with those be- fore the treatment （ P 〈 0.05 ）, and the decrease for the same type in rosuvastatin group was more notable than that in the routine treat- ment group （ P 〈 0.05 ）. The indices for different subgroups with various infarcts in rosuvastatin group were all lower than those for the same subgroup in the routine treatment group （P 〈0.05 ）. The incidence of adverse drug reactions （ADR） in two group was no signifi- cant difference （P 〉 0.05）. Conclusion： Rosuvastatin used in the patients with ACI has better clinical efficacy than the routine treat- ment, which can reduce the levels of MMp2, vasostatin-2 and sICAM-1 and is worthy of clinical promotion.